Tunlametinib

DRUG5 trials

Conditions

Advanced PDTC or ATC With NRAS MutationMelanomaMelanoma AdvancedMelanoma MetastaticNRAS MutationRadioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS MutationSolid Cancers

Phase 2

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

RecruitingNCT06970353

Fudan UniversityAdvanced PDTC or ATC With NRAS Mutation, Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation

Start: 2025-05-27End: 2031-12-30Target: 40Updated: 2025-08-07

Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors

RecruitingNCT07170293

Tianjin Medical University Second HospitalSolid Cancers

Start: 2027-08-31End: 2027-09-30Target: 15Updated: 2025-09-12

Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma

RecruitingNCT07750067

Sun Yat-sen UniversityMelanoma Metastatic, NRAS Mutation

Start: 2026-04-01End: 2030-07-28Target: 37Updated: 2026-08-10

Phase 3

Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

RecruitingNCT06008106

Shanghai Kechow Pharma, Inc.Melanoma

Start: 2023-11-02End: 2027-09-22Target: 165Updated: 2024-06-28

Phase 4

RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma

RecruitingNCT07445022

Fudan UniversityMelanoma Advanced

Start: 2026-01-28End: 2029-01-31Target: 110Updated: 2026-03-03

Related Papers

A phase III, open-label, multicenter, randomized controlled trial of tunlametinib versus investigator-selected chemotherapy in patients with advanced NRAS-mutant melanoma who had previously received immunotherapy.